Invitrx licenses fat-derived stem cell products to Bioheart

09/25/2013 | Pharmaceutical Business Review Online

Bioheart, which specializes in developing autologous cell treatments for heart damage and severe peripheral vascular disease, secured the rights to use Invitrx Therapeutics' adipose-based stem cell products under a licensing agreement. Bioheart could release preliminary results from an early-stage clinical study soon.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA